Answer
Yes, second primary cancers have been reported in patients receiving isatuximab, with an overall incidence of 6.1% among all isatuximab-exposed patients in the reported studies.
Sources for this answer
- SARCLISA 20mg/mL concentrate for solution for infusionSANOFI · emc · SmPC §4.4 Special warnings and precautions for use · Version 10Document updated
Sources checked